Research programme: liposomal therapeutics - Allergan/Merrimack
Latest Information Update: 30 Jul 2015
At a glance
- Originator Actavis Inc; Merrimack Pharmaceuticals
- Developer Merrimack Pharmaceuticals
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Unspecified
Most Recent Events
- 27 Nov 2013 Preclinical trials in Undefined indication in USA (unspecified route)